Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...
Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...
Subscriber growth surged 44% y/y to 2.05 million. It's also worth noting that ex-GLP 1 subgrowth would have been 40% y/y, ...
While there are hundreds of methods to make the scale move, many cost hundreds of dollars. That’s why Amazon shoppers are ...
In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...
One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from ...
Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...
You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor ...
Glucagon-like peptide medications that treat Type 2 diabetes and weight management continue to grow in popularity, though ...
A new study reveals patients may continue to take their GLP-1 receptor agonists before undergoing elective surgery or ...
Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback